
-
2004
Company Description
Anthera Pharmaceuticals is focused on developing products to treat diseases associated with inflammation and autoimmune diseases.
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.
-
Manufacturer:
Science and Engineering -
Formed:
2004 -
Company Website:
-
Company E-mail:
-
Company Address:
25801 Industrial Blvd, Suite BHayward, CAUnited States -
CEO:
- Renee Martin
-
We recognize our sponsors starting at $1 per entry.
Learn more at https://www.ithistory.org/benefits